XBiotech Inc.
NASDAQ:XBIT · NASDAQ Global Select
+$0.01 today
Vol 0.01M · Avg 0.03M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-32.4%
avg -21.1%
ROIC
-39.2%
avg -30.9%
ROA
-30.3%
avg -19.5%
Analysis
ROA is currently the strongest return metric at -30.3% versus its period average of -19.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
John Simard | Founder & Chairman | $27.13M | — | 64 | $1.90M | 6.22% |
Sushma Shivaswamy | Interim CEO & Chief Scientific Officer | $570,993.00 | — | 48 | $100,000.00 | 0.33% |
Angela Hu | Director of Finance | $245,419.00 | — | 42 | $0.00 | <0.01% |
Qian Wu | Senior Vice President of Clinical Operations & Analytical Quality | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A0 analysts |
| Net Income | N/A | N/A | N/A | N/A0 analysts |
| EBIT | N/A | N/A | N/A | N/A0 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Relmada Therapeutics, Inc.
NASDAQ:RLMD
$487.67M
Adagene Inc.
NASDAQ:ADAG
$134.41M
Fortress Biotech, Inc.
NASDAQ:FBIO
$92.02M
Adicet Bio, Inc.
NASDAQ:ACET
$75.25M
Gain Therapeutics, Inc.
NASDAQ:GANX
$71.66M
TScan Therapeutics, Inc.
NASDAQ:TCRX
$55.71M
Acrivon Therapeutics, Inc. Common Stock
ACRV
$46.70M
Nutriband Inc.
NTRB
$41.21M
Lite Strategy, Inc.
LITS
$25.22M
CervoMed Inc.
CRVO
$22.68M
Who manages XBIT?
XBiotech Inc. (XBIT) lists 4 active executives. The top listed executive is Sushma Shivaswamy, Interim CEO & Chief Scientific Officer.
Are XBIT insiders buying or selling?
Recent insider activity shows net selling of $411.92M.
Explore More
Continue the stock analysis
Jump to another research area for this company.